Literature DB >> 28774197

Thrombotic and Hemorrhagic Conditions Due to a Gain of Function of Coagulation Proteins: A Special Type of Clotting Disorders.

Antonio Girolami1, Elisabetta Cosi1, Silvia Ferrari1, Annamaria Lombardi1, Fabrizio Fabris1.   

Abstract

Coagulation disorders can be classified into 2 types, namely, type I and type II. In the former, there is a concomitant decrease in factor activity and antigen (activity-antigen ratio is 1), whereas in the latter, there is a discrepancy between factor activity which is always low and antigen which is normal or near normal (activity-antigen ratio is <1, eg, 0.5). Recently, several gain-of-function disorders have been described. These are characterized by an increased activity with respect to the antigen level. The condition involves polymorphisms of factor V and factor II, factor IX, von Willebrand disease, thrombomodulin, tissue factor pathway inhibitor, and thrombin activatable fibrinolysis inhibitor. The conditions could be subdivided into prothrombotic and prohemorrhagic. They should also be distinguished as cases of true gain of function (intrinsic increase activity without concomitant increase in protein level) and of "pseudo" gain of function (increase in both activity and protein level). This is a new concept of coagulation defects that has considerably enhanced our knowledge of blood coagulation and that should be familiar to all those interested in the mechanism of blood clotting and its disorders.

Entities:  

Keywords:  bleeding; coagulation; disorders; gain of function; thrombosis

Mesh:

Year:  2017        PMID: 28774197      PMCID: PMC6714700          DOI: 10.1177/1076029617721012

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  42 in total

1.  Prevalence of Factor IX-R338L (Factor IX Padua) in a cohort of patients with venous thromboembolism and mild elevation of factor IX levels.

Authors:  Bruna de Moraes Mazetto; Fernanda Loureiro Andrade Orsi; Lucia Helena Siqueira; Tayana Bezerra de Mello; Erich Vinícius de Paula; Joyce Maria Annichino-Bizzacchi
Journal:  Thromb Res       Date:  2010-06-01       Impact factor: 3.944

Review 2.  Genetic basis of thrombosis.

Authors:  Valeria Bafunno; Maurizio Margaglione
Journal:  Clin Chem Lab Med       Date:  2010-10-29       Impact factor: 3.694

3.  Characterization of a novel autosomal dominant bleeding disorder in a large kindred from east Texas.

Authors:  S Q Kuang; S Hasham; M D Phillips; D Wolf; Y Wan; P Thiagarajan; D M Milewicz
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

4.  Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences.

Authors:  A M Randi; I Rabinowitz; D J Mancuso; P M Mannucci; J E Sadler
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

5.  Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.

Authors:  A Casonato; A Steffan; E Pontara; A Zucchetto; C Rossi; L De Marco; A Girolami
Journal:  Thromb Haemost       Date:  1999-02       Impact factor: 5.249

Review 6.  The protein C pathway.

Authors:  Charles T Esmon
Journal:  Chest       Date:  2003-09       Impact factor: 9.410

7.  X-linked thrombophilia with a mutant factor IX (factor IX Padua).

Authors:  Paolo Simioni; Daniela Tormene; Giulio Tognin; Sabrina Gavasso; Cristiana Bulato; Nicholas P Iacobelli; Jonathan D Finn; Luca Spiezia; Claudia Radu; Valder R Arruda
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

8.  Three distinct point mutations in the factor IX gene of three Japanese CRM+ hemophilia B patients (factor IX BMNagoya 2, factor IX Nagoya 3 and 4).

Authors:  M Hamaguchi; T Matsushita; M Tanimoto; I Takahashi; K Yamamoto; I Sugiura; J Takamatsu; K Ogata; T Kamiya; H Saito
Journal:  Thromb Haemost       Date:  1991-05-06       Impact factor: 5.249

Review 9.  Congenital bleeding disorders of the vitamin K-dependent clotting factors.

Authors:  A Girolami; R Scandellari; M Scapin; S Vettore
Journal:  Vitam Horm       Date:  2008       Impact factor: 3.421

Review 10.  The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency.

Authors:  Antonio Girolami; Nicole Candeo; Silvia Vettore; Anna Maria Lombardi; Bruno Girolami
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.